Is laboratory monitoring of low-molecular-weight heparin therapy necessary?: yes

Ähnliche Einträge

• Biosimilars of low-molecular-weight heparin products: fostering competition or reducing ‘biodiversity’?
  von: Harenberg, Job
  Veröffentlicht: (2016)
• Patients’ plasma activity of heparin, low-molecular-weight heparin or no anticoagulants on urine based DOAC test strips
  von: Harenberg, Job, et al.
  Veröffentlicht: (2022)
• Treatment of patients initially for acute deep vein thrombosis with a low-molecular-weight heparin at a fixed, body weight-independent dosage
  von: Harenberg, Job, et al.
  Veröffentlicht: (2004)
• Low molecular weight heparins: planning a meta analysis based on original patient data
  Veröffentlicht: (1997)
• Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin
  von: Harenberg, Job, et al.
  Veröffentlicht: (2003)